Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ABC294640: Phase I/II started

    Apogee Biotechnology Corp., Hummelstown, Pa. RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat Gan, Israel Product: ABC294640 Business: Cancer Molecular target: Sphingosine kinase 2 (SPHK2) Description: Small …

    Published on 7/27/2015
  • ABX-1431: Phase Ia started

    Abide Therapeutics Inc., Princeton, N.J. Product: ABX-1431 Business: Neurology Molecular target: Monoacylglycerol lipase (MAGL) Description: Small molecule inhibitor of monoacylglycerol lipase (MAGL), which regulates 2-…

    Published on 7/27/2015
  • Ad26: Phase II started

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Ad26.ZEBOV Business: Infectious Molecular target: NA Description: Human adenovirus type 26 vector carrying Zaire Ebola virus glycoprotein Indication: Vaccinate …

    Published on 7/27/2015
  • AGS-003: Completed Phase III enrollment

    Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Product: AGS-003 Business: Cancer Molecular target: Not applicable Description: Second-generation RNA-loaded autologous dendritic cell immunotherapy Indication: Treat …

    Published on 7/27/2015
  • BeiGene-283: Phase Ib started

    BeiGene Co. Ltd., Beijing, China Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: BeiGene-283, BGB-283 Business: Cancer Molecular target: BRAF Description: Small molecule, second-generation BRAF inhibitor Indication:…

    Published on 7/27/2015
  • C2N-8E12: Phase I started

    C2N Diagnostics LLC, St. Louis, Mo. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: C2N-8E12, ABBV-8E12 Business: Neurology Molecular target: Microtubule-associated protein tau (tau) (MAPT) (FTDP-17) Description: …

    Published on 7/27/2015
  • Heplisav: Phase III ongoing

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Product: Heplisav (V270) Business: Infectious Molecular target: Hepatitis B surface antigen (HBsAg); Toll-like receptor 9 (TLR9) Description: HBV vaccine …

    Published on 7/27/2015
  • Human neural stem cells: Phase II started

    StemCells Inc. (NASDAQ:STEM), Newark, Calif. Product: Human neural stem cells (HuCNS-SC) Business: Ophthalmic Molecular target: Not applicable Description: Purified human neural stem cells Indication: Treat bilateral …

    Published on 7/27/2015
  • ISIS-HTTRx: Phase I/IIa started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: ISIS-HTTRx Business: Neurology Molecular target: Huntingtin (HTT) Description: Antisense molecule …

    Published on 7/27/2015
  • LIPO-202: Extension study started

    Neothetics Inc. (NASDAQ:NEOT), San Diego, Calif. Product: LIPO-202 Business: Other Molecular target: Adrenergic receptor beta 2 (ADRB2) Description: Subcutaneous formulation of salmeterol xinafoate, a long-acting …

    Published on 7/27/2015
  • Lorediplon: Phase IIa started

    Ergomed plc (LSE:ERGO), Guilford, U.K. Grupo Ferrer Internacional S.A., Barcelona, Spain Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Lorediplon Business: Neurology Molecular target: GABA A …

    Published on 7/27/2015
  • MVA-BN Filo: Phase II started

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: MVA-BN Filo Business: Infectious Molecular target: NA Description: Modified vaccinia Ankara (MVA) …

    Published on 7/27/2015
  • ProCervix: Phase II ongoing

    Genticel S.A. (Euronext:GTCL), Labege, France Product: ProCervix (GTL001) Business: Cancer Molecular target: Human papillomavirus (HPV) antigens Description: Bivalent therapeutic cancer vaccine against HPV types 16 and …

    Published on 7/27/2015
  • Rindopepimut: Phase III ongoing

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: Rindopepimut (Rintega) (CDX-110) (formerly PF-04948568) Business: Cancer Molecular target: Epidermal growth factor variant III (EGFRvIII) Description: …

    Published on 7/27/2015
  • SCIB1: Completed Phase I/II enrollment

    Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K. Product: SCIB1 Business: Cancer Molecular target: Tyrosinase-related protein 2 (TRP-2) (TYRP2) (DCT) Description: Cancer vaccine comprising the melanoma …

    Published on 7/27/2015
  • THR-184: Completed Phase II enrollment

    Thrasos Therapeutics Inc., Montreal, Quebec Product: THR-184 Business: Renal Molecular target: Activin receptor-like kinase 2 (ALK2) (ACVR1); Activin receptor-like kinase 3 (ALK3) Description: Small peptide that …

    Published on 7/27/2015
  • Vigil vaccine: Phase IIb start

    Gradalis Inc., Dallas, Texas Product: Vigil vaccine (formerly FANG vaccine) Business: Cancer Molecular target: Transforming growth factor (TGF) beta 1 (TGFB1); Transforming growth factor (TGF) beta 2 (TGFB2) Description…

    Published on 7/27/2015
  • VRS-317: Phase III ongoing

    Amunix Operating Inc., Mountain View, Calif. Versartis Inc. (NASDAQ:VSAR), Redwood City, Calif. Product: VRS-317 Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting recombinant human growth …

    Published on 7/27/2015
  • Zoptarelin doxorubicin acetate: Completed Phase III enrollment

    Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS), Quebec City, Quebec Ergomed plc (LSE:ERGO), Guilford, U.K. Product: Zoptarelin doxorubicin acetate (AEZS-108) (formerly ZEN-008, AN-152) Business: Cancer Molecular target: …

    Published on 7/27/2015
  • AG-881: Phase I started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: AG-881 Business: Cancer Molecular target: Isocitrate dehydrogenase 1 (IDH1); Isocitrate dehydrogenase 2 (IDH2…

    Published on 7/20/2015
  • Amantadine: Completed Phase III enrollment

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Neurology Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat …

    Published on 7/20/2015
  • APL-130277: Phase III started

    Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA), Toronto, Ontario Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine, a small…

    Published on 7/20/2015
  • Bertilimumab: Phase II started

    iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), New York, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab (iCo-008, CAT-…

    Published on 7/20/2015
  • BLZ-100: Phase I started

    Blaze Bioscience Inc., Seattle, Wash. Product: BLZ-100 (formerly CyTP 007) Business: Diagnostic Molecular target: NA Description: Variant of the peptide chlorotoxin, derived from scorpion venom, combined with a near-…

    Published on 7/20/2015
  • CPX-351: Phase II started

    Celator Pharmaceuticals Inc. (NASDAQ:CPXX), Ewing, N.J. Product: CPX-351 Business: Cancer Molecular target: DNA polymerase; Topoisomerase II (TOP2) Description: Liposomal formulation of cytarabine and daunorubicin …

    Published on 7/20/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993